Exhibit 99.1 Natera Reports Second Quarter 2024 Financial Results AUSTIN, Texas, August 8, 2024 /PRNewswire/ — Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and genetic testing, today reported its financial results for the second quarter ended June 30, 2024. Recent Strategic and Financial Highlights · Generated total revenues of $413.4 million in the second quarter of 2024, compared to $261.4 million in the second quarter of 2023, an increase of 58.1%. Product revenues grew 59.3% over the sa ...

Wall Street expects a year-over-year increase in earnings on higher revenues when Natera (NTRA) reports results for the quarter ended June 2024. While this widely-known consensus outlook is important in gauging the company's earnings picture, a powerful factor that could impact its near-term stock price is how the actual results compare to these estimates. The earnings report might help the stock move higher if these key numbers are better than expectations. On the other hand, if they miss, the stock may mo ...

Natera, Inc. (NASDAQ:NTRA) Q1 2024 Earnings Conference Call May 9, 2024 4:30 PM ET Company Participants Mike Brophy - Chief Financial Officer Steve Chapman - Chief Executive Officer Solomon Moshkevich - President, Clinical Diagnostics Alex Aleshin - General Manager Oncology and Chief Medical Officer Conference Call Participants Dan Brennan - TD Cowen Tejas Savant - Morgan Stanley Puneet Souda - Leerink Partners Doug Schenkel - Wolfe Research Catherine Schulte - Baird Matt Sykes - Goldman Sachs Operator Than ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ⌧ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 NATERA, INC. (Exact Name of Registrant as Specified in Its Charter) Delaware 01-0894487 (State or Other Jurisdiction of Incorporation or Organization) (I.R.S. Employer Identification No.) 13011 McCallen Pass Building A Suite 100 Austin, TX 78753 (Address of Principal Executive Offices) (Zip Code) (650) 980-919 ...

Natera (NTRA) reported $367.74 million in revenue for the quarter ended March 2024, representing a year-over-year increase of 52.1%. EPS of -$0.56 for the same period compares to -$1.23 a year ago.The reported revenue represents a surprise of +18.04% over the Zacks Consensus Estimate of $311.54 million. With the consensus EPS estimate being -$0.72, the EPS surprise was +22.22%.While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Str ...

Exhibit 99.1 Natera Reports First Quarter 2024 Financial Results AUSTIN, Texas, May 9, 2024 /PRNewswire/ — Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and genetic testing, today reported its financial results for the first quarter ended March 31, 2024. "We had an excellent start to the year, driving robust volume, revenue and margin growth and achieving cash flow breakeven earlier than expected," said Steve Chapman, chief executive officer of Natera. "We continued to deliver on our mission ...

Since inception, Natera (NASDAQ:NTRA) has incurred sustained losses, with their cash burn rate being one of the largest concerns to investors. However, the company seems to be on the verge of becoming profitable for the first time in its history. In my opinion, this is mostly due to the growth of the personalised medicines, particularly in oncology, together with the recently approved biomarkers law in 13 U.S. states. Thus, I consider that Natera as a “buy,” despite the risks associated with it. Personalise ...

Momentum investing is all about the idea of following a stock's recent trend, which can be in either direction. In the 'long' context, investors will essentially be "buying high, but hoping to sell even higher." And for investors following this methodology, taking advantage of trends in a stock's price is key; once a stock establishes a course, it is more than likely to continue moving in that direction. The goal is that once a stock heads down a fixed path, it will lead to timely and profitable trades.Even ...

AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced that it will participate in the following investor conferences in March. Raymond James 45th Annual Institutional Investors Conference Tuesday, March 5 at 2:15 pm ET | 11:15 am PT in Orlando, FL TD Cowen 44th Annual Health Care Conference Wednesday, March 6 at 9:50 am ET | 6:50 am PT in Boston, MA A live webcast and audio archive of each event may be accessed through the investor rela ...

Natera, Inc. (NASDAQ:NTRA) Q4 2023 Results Conference Call February 28, 2024 4:30 PM ET Company Participants Michael Brophy - Chief Financial Officer Steve Chapman - Chief Executive Officer Solomon Moshkevich - President, Clinical Diagnostics Alexey Aleshin - General Manager of Oncology & Chief Medical Officer John Fesco - President & Chief Business Officer Conference Call Participants Subbu Nambi - Guggenheim Puneet Souda - Leerink Partners David Westenberg - Piper Sander Tejas Savant - Morgan Stanley Doug ...